| |
| |
|
| Insider
Information: |
Neil Garry Arthur |
| Relationship: |
CEO and Chairman of th... |
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
49,979 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$18,280 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
49,979 |
|
|
| Total
Value |
$18,280 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
4
|
0
|
|
Stock
price went up :
|
2
|
0
|
| Stock
price went down : |
2
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 -27.7%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Aevi Genomic Medicine Inc |
GNMX |
Chief Scientific Officer |
2020-02-03 |
0 |
2014-12-01 |
0 |
Premium* |
|
|
Oncternal Therapeutics Inc |
ONCT |
Director |
2019-01-02 |
36,759 |
2016-09-01 |
0 |
Premium* |
|
|
Arena Pharmaceuticals Inc |
ARNA |
Director |
2022-03-11 |
0 |
2018-06-13 |
0 |
Premium* |
|
|
Avalo Therapeutics, Inc |
AVTX |
CEO and Chairman of th... |
2023-06-09 |
13,220 |
2020-02-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AVTX |
Avalo Therapeutics, Inc |
CEO and Chairman of the Board |
• • – |
2023-06-09 |
4 |
B |
$3.42 |
$13,680 |
D/D |
4,000 |
13,220 |
2.81 |
- |
|
| AVTX |
Avalo Therapeutics, Inc |
CEO and Chairman of the Board |
• • – |
2022-12-09 |
4 |
B |
$4.42 |
$9,207 |
D/D |
2,083 |
9,220 |
2.81 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
Director |
– • – |
2022-03-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(11,217) |
0 |
0 |
- |
|
| AVTX |
Avalo Therapeutics, Inc |
Chief Scientific Officer |
• – – |
2021-12-10 |
4 |
B |
$1.57 |
$6,699 |
D/D |
4,267 |
85,639 |
2.74 |
% |
|
| ARNA |
Arena Pharmaceuticals Inc |
Director |
– • – |
2021-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,067 |
11,217 |
0 |
- |
|
| AVTX |
Avalo Therapeutics, Inc |
Chief Scientific Officer |
• – – |
2021-06-10 |
4 |
B |
$2.28 |
$8,418 |
D/D |
3,692 |
81,372 |
2.74 |
% |
|
| AVTX |
Avalo Therapeutics, Inc |
Chief Scientific Officer |
• – – |
2020-12-10 |
4 |
B |
$2.28 |
$8,199 |
D/D |
3,599 |
77,680 |
2.74 |
% |
|
| ARNA |
Arena Pharmaceuticals Inc |
Director |
– • – |
2020-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,446 |
8,150 |
0 |
- |
|
| AVTX |
Avalo Therapeutics, Inc |
Chief Scientific Officer |
• – – |
2020-06-10 |
4 |
B |
$2.28 |
$4,098 |
D/D |
1,799 |
74,081 |
2.66 |
% |
|
| AVTX |
Avalo Therapeutics, Inc |
Chief Medical Officer |
• – – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
72,282 |
72,282 |
0 |
- |
|
| GNMX |
Aevi Genomic Medicine Inc |
Chief Scientific Officer |
• – – |
2020-02-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,164,150) |
0 |
0 |
- |
|
| GNMX |
Aevi Genomic Medicine Inc |
Chief Scientific Officer |
• – – |
2019-12-05 |
4 |
B |
$0.13 |
$274,616 |
D/D |
2,049,376 |
2,164,150 |
2.74 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
2,654 |
5,704 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Director |
– • – |
2019-01-02 |
4 |
A |
$0.86 |
$12,500 |
D/D |
14,535 |
36,759 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Director |
– • – |
2018-10-01 |
4 |
A |
$1.50 |
$12,500 |
D/D |
8,333 |
22,224 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Director |
– • – |
2018-07-02 |
4 |
A |
$15.47 |
$12,500 |
D/D |
808 |
13,891 |
0 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
Director |
– • – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
3,050 |
3,050 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Director |
– • – |
2018-04-02 |
4 |
A |
$17.47 |
$12,500 |
D/D |
716 |
13,083 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Director |
– • – |
2018-01-02 |
4 |
A |
$11.46 |
$12,500 |
D/D |
1,091 |
12,367 |
0 |
- |
|
| GNMX |
Aevi Genomic Medicine Inc |
Chief Scientific Officer |
• – – |
2017-10-17 |
4 |
B |
$1.26 |
$94,500 |
D/D |
75,000 |
114,774 |
2.74 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Director |
– • – |
2017-10-02 |
4 |
A |
$7.94 |
$12,500 |
D/D |
1,574 |
11,277 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Director |
– • – |
2017-04-03 |
4 |
A |
$4.90 |
$12,500 |
D/D |
2,551 |
7,326 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Director |
– • – |
2017-01-03 |
4 |
A |
$5.21 |
$12,500 |
D/D |
2,399 |
4,775 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Director |
– • – |
2016-10-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,447 |
23,757 |
0 |
- |
|
| ONCT |
Oncternal Therapeutics In... |
Director |
– • – |
2016-09-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,310 |
7,310 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
